CancerWorld shared a post on LinkedIn:
“The Day Immunotherapy Went Off-Patent
Nivolumab changed cancer care. Five-year survival in advanced melanoma jumped from 10–15% to nearly 50%. Lung, kidney, and other cancers saw outcomes once thought impossible.
Now its patent is expiring. Biosimilars are arriving, prices may fall, and access could widen especially in regions long left behind.
A quiet milestone for headlines. A seismic shift for patients. Science succeeded. The next challenge: making survival global.
Read the full CancerWorld article by Dr. Amalya Sargsyan here.”
See other articles from CancerWorld on OncoDaily.